# Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)

> **NCT03395340** · PHASE2 · TERMINATED · sponsor: **National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)** · enrollment: 1 (actual)

## Conditions studied

- Graft Versus Host Disease
- JNS Kinase
- Topical Administration

## Interventions

- **DRUG:** Ruxolitinib 1.5% cream
- **DRUG:** vehicle cream

## Key facts

- **NCT ID:** NCT03395340
- **Lead sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-19
- **Primary completion:** 2019-01-31
- **Final completion:** 2019-01-31
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Forced to close study due to poor recruitment (company withdrew drug support).
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03395340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03395340, "Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03395340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*